Open Access

Clinical characteristics and prognosis of gastrointestinal stromal tumors with rare site metastasis (Review)

  • Authors:
    • Xinhui Yu
    • Xiaoxiang Liang
    • Kunming Wen
  • View Affiliations

  • Published online on: November 1, 2022     https://doi.org/10.3892/ol.2022.13573
  • Article Number: 453
  • Copyright: © Yu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Gastrointestinal stromal tumors (GIST) are the most common stromal‑derived tumors of the gastrointestinal tract and have a potential metastatic capacity in almost half of all cases, with the most common sites of metastasis being the liver and peritoneum. However, there is evidence that GIST metastasizes to sites other than the liver and peritoneum, which poses challenges for clinical diagnosis and treatment. Therefore, the Cochrane and Medline databases were searched via PubMed in July 2022 using relevant keywords to acquire the literature associated with the metastasis of GIST to rare sites published since from 2000 onwards. Study data comprising age, sex, primary location, metastatic site, mean survival time, clinical signs and symptoms, imaging, pathological features immunohistochemical indices, treatment and prognosis were recorded and analyzed. The 118 metastases at rare sites reported in the literature included bone (n=31), lung (n=10), lymph nodes (n=13), intracranial sites (n=13), skin and subcutaneous tissue (n=10), heart (n=7), skeletal muscle (n=7), orbit and choroid (n=6), pancreas (n=3), spleen (n=2), bone marrow (n=1), testis (n=3), scrotum (n=1), epididymis (n=1), penis (n=1), ovary (n=2), cervix (n=1), kidney (n=1), bladder (n=1), adrenal gland (n=2) and thyroid gland (n=2). From the reviewed studies, it may be concluded that when metastases from gastrointestinal stromal tumors occur at rare sites, the initial symptoms may help in the identification of these sites. In addition, the site‑dependent imaging of different metastatic locations may further define the metastases, and the findings of pathological or immunohistochemical analyses may be used to confirm the diagnosis.
View Figures
View References

Related Articles

Journal Cover

December-2022
Volume 24 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yu X, Liang X and Wen K: Clinical characteristics and prognosis of gastrointestinal stromal tumors with rare site metastasis (Review). Oncol Lett 24: 453, 2022
APA
Yu, X., Liang, X., & Wen, K. (2022). Clinical characteristics and prognosis of gastrointestinal stromal tumors with rare site metastasis (Review). Oncology Letters, 24, 453. https://doi.org/10.3892/ol.2022.13573
MLA
Yu, X., Liang, X., Wen, K."Clinical characteristics and prognosis of gastrointestinal stromal tumors with rare site metastasis (Review)". Oncology Letters 24.6 (2022): 453.
Chicago
Yu, X., Liang, X., Wen, K."Clinical characteristics and prognosis of gastrointestinal stromal tumors with rare site metastasis (Review)". Oncology Letters 24, no. 6 (2022): 453. https://doi.org/10.3892/ol.2022.13573